---
title: "CMS finalizes new Medicare DRG reimbursement codes for Carlsmed aprevo lumbar fusion procedures"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294692142.md"
description: "CMS finalized FY27 IPPS changes creating new MS-DRGs (523, 524, 525) for Carlsmed's aprevo lumbar fusion procedures. These codes cover complex spinal fusions excluding cervical cases across various severity tiers. The new assignments take effect on October 1, 2026, establishing Medicare inpatient payment rates for eligible procedures."
datetime: "2026-08-03T12:19:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294692142.md)
  - [en](https://longbridge.com/en/news/294692142.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294692142.md)
---

# CMS finalizes new Medicare DRG reimbursement codes for Carlsmed aprevo lumbar fusion procedures

-   CMS finalized FY27 IPPS reimbursement changes that create new MS-DRGs for aprevo lumbar inpatient spinal fusion procedures. \* Procedures were reassigned to MS-DRGs 523, 524, 525, covering extensive or complex spinal fusion except cervical across MCC, CC, no CC/MCC tiers. \* New MS-DRG assignments take effect Oct. 1, 2026, setting Medicare inpatient payment rates for eligible aprevo lumbar cases. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carlsmed Inc. published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CARL.US](https://longbridge.com/en/quote/CARL.US.md)

## Related News & Research

- [Carlsmed Eyes Growth as Cervical Launch, Medicare Shift Boost Spine Platform](https://longbridge.com/en/news/295727323.md)
- [Carlsmed Q2 net loss widens 55.3% to $10.51 million; revenue rises 57% to $18.9 million](https://longbridge.com/en/news/295006429.md)
- [Bone Biologics extends rhNELL-1 shelf life to 32 months as NB1 spine fusion trial advances](https://longbridge.com/en/news/295662468.md)
- [08:06 ETNeuralytix Announces Full Commercial Availability of iD3 System for Intraoperative Nerve Assessment in Spine Surgery](https://longbridge.com/en/news/295662144.md)
- [Chemours (NYSE:CC) CEO Acquires $50,501.10 in Stock](https://longbridge.com/en/news/295857681.md)